XNYS
RCUS
Market cap1.04bUSD
Jul 28, Last price
9.85USD
1D
-3.71%
1Q
21.16%
IPO
-44.03%
Name
Arcus Biosciences Inc
Chart & Performance
Profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
Income | |||||||||
Revenues | 258,000 120.51% | 117,000 4.46% | 112,000 -70.75% | ||||||
Cost of revenue | 568,000 | 797,000 | 406,000 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (310,000) | (680,000) | (294,000) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 1,000 | 6,000 | 1,000 | ||||||
Tax Rate | |||||||||
NOPAT | (311,000) | (686,000) | (295,000) | ||||||
Net income | (283,000) -7.82% | (307,000) 14.98% | (267,000) -603.77% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 228,000 | 25,000 | 23,000 | ||||||
BB yield | -16.99% | -1.77% | -1.54% | ||||||
Debt | |||||||||
Debt current | 11,000 | 3,000 | |||||||
Long-term debt | 60,000 | 11,000 | 234,000 | ||||||
Deferred revenue | 307,000 | 355,000 | |||||||
Other long-term liabilities | 391,000 | 142,000 | 140,000 | ||||||
Net debt | (918,000) | (844,000) | (1,030,000) | ||||||
Cash flow | |||||||||
Cash from operating activities | (170,000) | (306,000) | 438,000 | ||||||
CAPEX | (6,000) | (24,000) | (12,000) | ||||||
Cash from investing activities | (84,000) | 194,000 | (413,000) | ||||||
Cash from financing activities | 277,000 | 33,000 | 33,000 | ||||||
FCF | (307,000) | (702,000) | (192,577) | ||||||
Balance | |||||||||
Cash | 978,000 | 759,000 | 1,138,000 | ||||||
Long term investments | 107,000 | 129,000 | |||||||
Excess cash | 965,100 | 860,150 | 1,261,400 | ||||||
Stockholders' equity | 485,000 | 462,000 | 657,000 | ||||||
Invested Capital | 439,000 | 460,000 | 615,000 | ||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 90,100 | 74,000 | 72,000 | ||||||
Price | 14.89 -22.04% | 19.10 -7.64% | 20.68 -48.90% | ||||||
Market cap | 1,341,589 -5.08% | 1,413,400 -5.07% | 1,488,960 -50.26% | ||||||
EV | 423,589 | 569,400 | 458,960 | ||||||
EBITDA | (300,000) | (672,000) | (288,000) | ||||||
EV/EBITDA | |||||||||
Interest | 4,000 | 2,000 | 2,000 | ||||||
Interest/NOPBT |